Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12607816 | 0.93 | ENPP2 (0.52) | ENPP2PRMT5WDR77MCHR1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL1783579 | 0.84 | DPP4 (0.45) | ENPP2PRMT5WDR77MCHR1DPP4 | |
| Trifluoroacetic Acid SCHEMBL1791141 | 0.81 | OPRM1 (0.54) | PRMT5WDR77OPRM1RIPK1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL3345248 | 0.80 | DPP4 (0.48) | PRMT5WDR77DPP4DPP8DPP9 | |
| SCHEMBL1786439 | 0.80 | MGLL (0.46) | PRMT5WDR77MCHR1HRH3 | |
| SCHEMBL12607818 | 0.76 | TMEM97 (0.62) | PRMT5WDR77OPRM1OPRK1OPRD1 | |
| SCHEMBL12607809 | 0.76 | FAAH (0.44) | ENPP2PRMT5WDR77OPRM1RIPK1 | |
| Hydrochloric Acid SCHEMBL1785554 | 0.75 | TMEM97 (0.61) | PRMT5WDR77OPRM1OPRK1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL3339550 | 0.74 | DPP4 (0.42) | PRMT5WDR77DPP4DPP8DPP9 | |
| SCHEMBL12607826 | 0.74 | OPRM1 (0.59) | PRMT5WDR77OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | ENPP2 869/4885PRMT5 3222/4885WDR77 1787/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | ENPP2 618/4885PRMT5 1975/4885WDR77 974/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | ENPP2 869/4885PRMT5 3222/4885WDR77 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.